ArticleRSC advances2025
Structure-based design of orthosteric and allosteric CCR2 inhibitors for potential IPF therapy.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ultrasound-Assisted Ternary Deep Eutectic Solvent Extraction of Total Flavonoids fromAntioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal respiratory disease with an extremely poor prognosis. Our previous studies revealed that CCR2 (C-C chemokine receptor type 2) expression is significantly upregulated in bleomycin-induced pulmonary fibrosis in mice. Moreover, bioinformatics analysis indicated that higher CCR2 expression is associated with poorer prognosis in patients. Therefore, we proposed a novel dual-target intervention strategy focused on the orthosteric and allosteric binding sites of the CCR2 receptor. By integrating structure-based pharmacophore modeling, 3D-QSAR, common feature pharmacophore modeling, and large-scale virtual screening (covering 152 406 molecules), we successfully identified two candidate small molecules, compound 17 and compound 67, that exhibit high site selectivity. Molecular dynamics (MD) simulations, principal component analysis (PCA), and potential energy surface analyses
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.